{"entity":{"id":"paper-yu-ga68-my6349-breast-theranostics-2026","kind":"paper","name":"Trop2-targeted PET/CT imaging with 68Ga-MY6349 improves diagnostic accuracy and influences clinical management in breast cancer","aka":[],"tldr":"In 73 people with breast cancer, a TROP2 PET scan found more cancer deposits than a standard FDG scan, with fewer false alarms, and changed treatment for some.","summary":"73 patients with suspected or confirmed breast cancer had both 68Ga-MY6349 and 18F-FDG PET/CT between December 2024 and April 2025. 68Ga-MY6349 found more malignant lesions (564 against 436) and fewer false positives (2 against 40). In 30 initial-staging patients it upgraded stage in 6 (20 per cent) and changed treatment in 4; in 43 restaging patients it changed management in 5 (12 per cent). Overall tumour uptake was higher (median maximum standardised uptake value 5.9 against 4.1, p < 0.001). In three patients with triple-negative breast cancer on sacituzumab tirumotecan, early changes in uptake after two cycles matched the later clinical response; the authors call this preliminary.","asOf":"2026-11-04","links":[{"label":"Yu et al., Theranostics 2026","url":"https://doi.org/10.7150/thno.136704"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42559486/"}],"tags":[],"related":[],"cancers":["breast-cancer","tnbc"],"sections":["imaging"],"technologies":["trop2-pet","pet"],"targets":["trop2"],"drugs":["ga68-my6349","sacituzumab-tirumotecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"Theranostics","year":2026,"doi":"10.7150/thno.136704","pmid":"42559486","authors":"Yu L, Zhao L, Zeng R, et al.","paperType":"observational","findings":["564 vs 436 malignant lesions; 2 vs 40 false positives compared with FDG.","Stage upgraded in 6 of 30; management changed in 4 of 30 and 5 of 43.","Early uptake change matched response in 3 TNBC patients on sacituzumab tirumotecan."],"whatItMeans":"A TROP2 scan may help stage breast cancer and, if the early signal holds, judge whether a TROP2 drug is working. It images visible disease, not residual disease after surgery.","caveats":["Single centre; the treatment-response finding rests on three patients."],"participants":73},"route":"/key-papers/paper-yu-ga68-my6349-breast-theranostics-2026/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"}],"technology":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/"},{"id":"trop2-pet","kind":"technology","name":"TROP2 PET","route":"/technologies/trop2-pet/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"ga68-my6349","kind":"drug","name":"68Ga-MY6349","route":"/drugs/ga68-my6349/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}]}}